| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3286 |
| Trial ID | NCT05664217 |
| Disease | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Non-Hodgkin's Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Co-treatment | NKTR-255 |
| Phase | Phase2|Phase3 |
| Recruitment status | Recruiting |
| Title | NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma |
| Year | 2022 |
| Country | United States |
| Company sponsor | Nektar Therapeutics |
| Other ID(s) | 18-255-01 |
| Cohort 1 | |||||||||
|
|||||||||